Dabur Pharma news from FiercePharma
News
ALSO NOTED: Bayer sues Watson over Yasmin; Zimmer weeds out doc conflicts
> Open another chapter in the Bayer fight to protect Yasmin patents: Watson Pharmaceuticals filed for FDA approval for its copycat version of the birth control pill, and Bayer sued to keep the Read more...
ALSO NOTED: Appeals court votes for FDA approval shield; Suicides rose as depression treatment fell;
> A federal appeals court backed the drug industry's arguments that it should be insulated from lawsuits over FDA-approved products, ruling 2-1 that antidepressant makers GlaxoSmithKline and Read more...
ALSO NOTED: German Merck wants to make pharma buys; Novartis breast-cancer med prevents recurrence;
> Merck KGaA is on the prowl for pharma acquisitions, CEO Ludwig Kley told a German newspaper. Report > Read more...
SPOTLIGHT: Dabur gets nod for generic Camptosar
India's Dabur Pharma got the FDA's tentative OK to sell a generic version of Camptosar, Pfizer's colon cancer treatment. Read more...
ALSO NOTED: Strong euro hitting Merck KGaA's revenue; U.S. sales boost Lupin's Q3 profits;
> German pharma Merck KGaA says a strong euro will depress its year-end sales; it reported a 74.9 percent drop in third-quarter profits on a one-time charge from its acquisition of Serono. Read more...
SPOTLIGHT: Ellence knockoff OK'd
Indian generics maker Dabur Pharma got the FDA's nod for its version of the Pfizer breast-cancer treatment Ellence, a $60 million-per-year drug in the U.S. It's Dabur's third FDA approval in twelve Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends